Evidence map›Paper›PMID 39650055›Full record

ArticleFrontiers in oncology2024

SLNP-based CDK4- targeted nanotherapy against glioblastoma.

Uzma Ghani, Fareeha Khalid Ghori, Muhammad Usman Qamar, Hina Khan, Basit Azad, Sabahat Habib, Saira Justin, Ishaq N Khan, Tawaf Ali Shah, Gamal A Shazly and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Uzma GhaniMolecular Immunology Laboratory, Department of Healthcare Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan.
Fareeha Khalid GhoriMolecular Immunology Laboratory, Department of Healthcare Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan.
Muhammad Usman QamarInstitute of Microbiology, Faculty of Life Sciences, Government College University Faisalabad, Faisalabad, Pakistan.
Hina KhanMolecular Immunology Laboratory, Department of Healthcare Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan.
Basit AzadMaterials And Modeling Lab, School of Interdisciplinary Engineering and Sciences, National University of Sciences and Technology, Islamabad, Pakistan.
Sabahat HabibMolecular Immunology Laboratory, Department of Healthcare Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan.
Saira JustinMolecular Immunology Laboratory, Department of Healthcare Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan.
Ishaq N KhanCancer Cell Culture and Precision Oncomedicine Lab, Institute of Basic Medical Sciences (IBMS), Khyber Medical University, Peshawar, Pakistan.
Tawaf Ali ShahCollege of Agriculture Engineering and Food Sciences, Shandong University of Technology, Zibo, China.
Gamal A ShazlyDepartment of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Mohammed BourhiaDepartment of Chemistry and Biochemistry, Faculty of Medicine and Pharmacy, Ibn Zohr University, Laayoune, Morocco.
Fouzia PerveenMaterials And Modeling Lab, School of Interdisciplinary Engineering and Sciences, National University of Sciences and Technology, Islamabad, Pakistan.
Aneela JavedMolecular Immunology Laboratory, Department of Healthcare Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Glioblastoma is a grade IV solid brain tumor and has a 15-month survival rate even after treatment. Glioblastoma development is heavily influenced by retinoblastoma protein (pRB) pathway changes. The blood-brain barrier, drug resistance, and severe toxicity of Temozolamide are key obstacles in treating glioblastoma. Innovative treatments targeting the pRB pathway with efficient delivery vehicles are required to treat glioblastoma. Methods: For this purpose, a library of 691 plant extracts previously tested Results: Silymarin (Sil) was identified as the most potent compound against CDK4, which was then encapsulated in stearic acid solid lipid nanoparticles (SLNP-Sil). Sil showed decreased cell viability 72 h after treatment against both U87 and U251 cell lines but had negligible cytotoxic effect on HEK-293. IC50 value of Sil was 155.14 µM for U87 and 195.93 µM for U251. Sil and SLNP-Sil effectively inhibited U87 and U251 cell migration 24 h after treatment. Discussion: Our results indicated that Sil and SLNP-Sil are promising therapeutic approaches against glioblastoma and merit

Indexed as

blood brain barrierglioblastomasilymarinsolid lipid nanoparticlestemozolamide

Identifiers

PMID39650055
PMCPMC11621005

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.